Skip to main navigation
Skip to search
Skip to main content
Research Explorer The University of Manchester Home
Home
Research Profiles
Research units
Research output
Projects
Impacts
Activities
Press/Media
Prizes
Equipment
Datasets
Student theses
Search by expertise, name or affiliation
Brodalumab in psoriasis: Evidence to date and clinical potential
Amy C. Foulkes
,
Richard B. Warren
Division of Musculoskeletal & Dermatological Sciences (L5)
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Brodalumab in psoriasis: Evidence to date and clinical potential'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Brodalumab
100%
Psoriasis
60%
Diseases
40%
Interleukin 17
40%
Psoriasis Vulgaris
20%
Cytokine
20%
Depression
20%
Human Monoclonal Antibody
20%
Suicidal Ideation
20%
Immunoglobulin G2
20%
Interleukin 17 Receptor
20%
Immunology and Microbiology
Brodalumab
100%
Interleukin 17
40%
Electric Potential
20%
Human Monoclonal Antibody
20%
Immunoglobulin G2
20%
Interleukin-17 Receptor
20%